KAT5 and skin neoplasm: Together our results suggest that targeting the TIP60/ΔNp63α axis may sensitize resistant SCC cancer to cisplatin and points to the potential utility of TIP60 inhibition as an adjunct therapy to overcome cisplatin resistance, offering a promising new avenue for therapeutic interventions in non-melanoma skin cancer.